Digital health technologies for the prevention and management of urinary tract infections in menopausal women: A systematic review.

MaturitasOct 7, 2026 (epub)

E Cappelli, M A Cappelli, F Cappelli et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review synthesised evidence on digital technologies for preventing or managing urinary tract infections in menopausal women. Searches of four databases identified 14 eligible studies; evidence certainty ranged from very low to moderate. Across varied tools, digital interventions reduced inappropriate antibiotic prescribing by up to 60% and ciprofloxacin use by 80.5%. Predictive models showed discrimination values of 0.57–0.96 but lacked prospective validation. One randomised controlled trial found increased uptake of vaginal oestrogen therapy with digital support. The review found that existing technologies rarely incorporated menopause-specific biological factors.

Key findings

  • Digital tools reduced inappropriate antibiotic prescribing by up to 60% and ciprofloxacin use by 80.5%.
  • Predictive models achieved discrimination values of 0.57-0.96, but none had prospective validation.
  • One randomised controlled trial found increased uptake of vaginal oestrogen therapy with digital support.
  • No study used formal reproductive-aging staging or integrated hormonal variables; time to diagnosis and treatment was not assessed.

Why it matters

Digital approaches may support antimicrobial stewardship and non-antibiotic prevention in a population with increased UTI susceptibility after menopause. However, the evidence base is limited and technologies have not adequately accounted for menopause-specific biology. These gaps matter when interpreting model performance and considering whether digital tools can support care tailored to menopausal status.

What to keep in mind

Evidence certainty ranged from very low to moderate. Predictive models lacked prospective validation, and studies did not assess time to diagnosis or treatment or incorporate formal menopause staging and hormonal variables.

Source

Published in Maturitas. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.